MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.sleep.2025.02.012

Медицинская библиотека · Sleep medicine · 2025

Interim analysis of a post-authorization safety study of pitolisant in treating narcolepsy: A real-world European study.

Plazzi Giuseppe, Mayer Geert, Bodenschatz Ralf, Bonanni Enrica, Cicolin Alessandro, Della Marca Giacomo, Dolso Pierluigi, Strambi Luigi Ferini, Ferri Raffaele, Geisler Peter, Happe Svenja, Heidbreder Anna, Herold Jürgen, Kallweit Ulf, Leclair-Visonneau Laurène, Lederer Katharina, Liguori Claudio, Meurling Johan, Parrino Liborio, Proserpio Paola, Puligheddu Monica, Quera Salva Maria Antonia, Remi Jan, Romigi Andrea, Rupprecht Sven, Savarese Maria Antonietta, Schaff Jean-Luc, Terzaghi Michele, Winter Yaroslav, Caussé Christian, Collin Irène, Lecomte Isabelle, Dauvilliers Yves

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Narcolepsy is a chronic sleep disorder characterized mainly by excessive daytime sleepiness (EDS) and cataplexy in the case of narcolepsy type 1 (NT1). Pitolisant is a histamine 3 receptor antagonist/inverse agonist that reduces EDS and cataplexy in patients with narcolepsy.

METHODS

We performed a prospective 5-year follow-up, non-interventional study of adults with NT1 and NT2 receiving pitolisant. The primary objectives were to collect information on the long-term safety of pitolisant and analyze the utilization patterns of pitolisant. The secondary objectives were to assess clinical benefit, adherence, impact on patients' quality of life, disease burden, and patient satisfaction. We reported the results of an interim analysis after 42.6 months.

RESULTS

The population comprised 370 patients (mean age, 40 ± 15 years; 51.4 % women; NT1, 71.4 %; NT2, 28.6 %); 364 received ≥1 dose of pitolisant. Data were available for 356 patients (97.8 %). Most patients (68.4 %) had ≥1 comorbidity (obesity [BMI≥30], 31.9 %; neuropsychiatric, 31 %; and cardiovascular, 22.8 %). Forty-eight patients (13.2 %) had received no prior narcoleptic treatment, while 98 (31 %) were taking a previous therapy, which was switched to pitolisant. Treatment was combined with pitolisant in 218 (69 %) patients. Pitolisant was discontinued by 131 patients (35.4 %), mainly for safety reasons (14.3 %), lack of response (8.7 %), and patient decision (7.6 %). Overall, 355 treatment-emergent adverse events (3 serious) were reported by 156 patients (42.9 % of safety population), with 218 possibly treatment-related (61.4 %) in 109 patients (29.9 %). Improvements were observed in EDS, cataplexy, and quality of life.

CONCLUSIONS

Pitolisant was generally safe and well tolerated in patients with NT1 and NT2 and can be used in both types. Improvements were found in EDS, cataplexy, and quality of life, with good adherence and satisfaction.

Для цитирования: Plazzi Giuseppe, Mayer Geert, Bodenschatz Ralf, Bonanni Enrica, Cicolin Alessandro, Della Marca Giacomo, Dolso Pierluigi, Strambi Luigi Ferini, Ferri Raffaele, Geisler Peter, Happe Svenja, Heidbreder Anna, Herold Jürgen, Kallweit Ulf, Leclair-Visonneau Laurène, Lederer Katharina, Liguori Claudio, Meurling Johan, Parrino Liborio, Proserpio Paola, Puligheddu Monica, Quera Salva Maria Antonia, Remi Jan, Romigi Andrea, Rupprecht Sven, Savarese Maria Antonietta, Schaff Jean-Luc, Terzaghi Michele, Winter Yaroslav, Caussé Christian, Collin Irène, Lecomte Isabelle, Dauvilliers Yves. Interim analysis of a post-authorization safety study of pitolisant in treating narcolepsy: A real-world European study.. Sleep medicine. 2025. DOI: 10.1016/j.sleep.2025.02.012.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.